Positive Data from Levicept’s Phase II Study of LEVI-04

Positive Data from Levicept’s Phase II Study of LEVI-04 in the Treatment of Patients with Moderate to Severe Osteoarthritis to be Presented at Forthcoming International Medical Congresses this Month Sandwich, UK – 7 April 2025 – Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting key data from its positive Phase II trial of LEVI-04 at a number of important international medical meetings during April. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, (WCO- IOF-ESCEO) Rome, Italy 10 – 13 April Title: Results from a Randomised Controlled Phase II Trial with LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrate Substantially Improved Pain and Function Without Deleterious Effects on Joint Structure in People With Knee Osteoarthritis • Presenter: Principal Investigator Prof. Philip Conaghan, University of Leeds • Oral presentation: 11 April, 11:20 am BST, Auditorium A See full programme here: https://www.wco-iof-esceo.org/programme 2025 World Congress on Osteoarthritis (OARSI2025), Seoul, Korea 24 – 27 April Title: LEVI-04, a Novel Neurotrophin-3 Inhibitor, Substantially Improves Pain and Function in People with Knee Osteoarthritis: a Randomised Controlled Phase II Trial. • Presenter: Prof. Philip Conaghan, University of Leeds • Oral plenary presentation: 26 April 2025, 10:45 - 10:55 am BST, Location: P5 Title: LEVI-04, a novel neurotrophin-3 inhibitor, is not associated with deleterious effects on joint structure in people with knee osteoarthritis: data from a Phase II RCT. • Presenter: Prof. Ali Guermazi, Boston University School of Medicine • Poster #410: 25 April and 26 April 4:15 – 5:00 pm BST, Grand Ballroom C See full programme here: https://congress.oarsi.org/program British Society for Rheumatology (BSR) 2025 Annual Meeting, Manchester, UK 28 – 30 April Title: A randomised controlled Phase II trial of LEVI-04, a novel neurotrophin-3 inhibitor, in knee osteoarthritis demonstrates substantially improved pain and function without deleterious effects on joint structure. • Presenter: Principal Investigator Prof. Philip Conaghan, University of Leeds • Oral presentation #OA04: 28 April, 9:45 - 10:00 am BST See full programme here: https://www.rheumatology.org.uk/eventslearning/conferences/annualconference Eliot Forster, CEO of Levicept, said, “We look forward to presenting our exciting data and the opportunity to meet others working to tackle the urgent need for better treatments for the hundreds of millions of people whose lives are blighted by osteoarthritis and by pain. We believe that LEVI-04 has the potential to become a genuine breakthrough in the treatment of osteoarthritis.” - ENDS Levicept Eliot Forster, CEO – [email protected] Media Enquiries Charles Consultants Sue Charles - [email protected] +44 (0)7968 726585 Chris Gardner - [email protected] +44 (0)7956 031077 About Levicept – www.levicept.com Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04 [p75NTR-Fc], for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI -04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures. Follow us on LinkedIn - https://www.linkedin.com/company/levicept-ltd

The release as fetched from its publisher. levicept.com ↗